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The National Tuberculosis Directorate is 
reviewing the relative cost and staffing 
implications of earlier ARV treatment 
for HIV co-infected patients following 
breakthrough research in Durban that 
could save up to 10 000 more lives a 
year.
This was confirmed by directorate 
chief, Dr Lindiwe Mvusi, who said the 
trial by the University of KwaZulu-
Natal’s Centre for the AIDS Programme 
of Research in South Africa (Caprisa) 
begged an urgent decision on where to 
reset the government’s current 200 CD4 
cell count ART initiation bar. Until now 
there had been no clinical trial evidence 
worldwide to prove that treating people 
concurrently for HIV and TB saves lives.
Caprisa director, Professor Salim 
Abdool Karim, said the study of 645 
patients with CD4 cell counts of less 
than 500, definitively showed that HIV 
patients co-infected with TB did worse 
than those without TB, regardless of 
their CD4 count.
Traditionally, doctors have first 
attempted to cure patients of TB 
and only then start them on ARV 
medication. This is because one of the 
TB drugs interacts with some ARVs, 
reducing their effectiveness. It also 
spares patients from taking up to 7 
pills a day. However, the Durban study 
shows that mortality among TB-HIV 
co-infected patients can be reduced by a 
remarkable 55% if ART is provided with 
TB treatment.
The results were welcomed by 
UNAIDS executive director, Dr Peter 
Piot, who emphasised that TB was the 
leading cause of death in people living 
with HIV, and by Dr Francois Venter, 
head of the SA HIV Clinicians Society. 
Venter said the study had ‘begun to 
answer one of the most important 
questions for the HIV field – when we 
can start ARVs safely in people with 
TB’.
Rapid diagnosis of HIV in TB clinics 
and getting such patients onto ARVs 
was vital.
‘Saving 10 000 lives (nationally) a 
year by improving a programme that 
desperately needs strengthening should 
be a priority,’ Venter added.
Trial description and results
Caprisa started the three-arm trial in 
2005 to test whether patients with TB 
and HIV and CD4 counts of under 500 
should:
•    be given both TB medicine and 
ARVs together as soon as possible
•    be treated intensively for TB for 2 
months and then started on ARVs or 
•    only be given ARVs after completing 
TB treatment (a wait of 6 - 8 months).
Twice as many patients died in the 
group that waited for ARVs until they 
had completed TB treatment than those 
in the two groups where ARVs and TB 
treatment were integrated. As soon as 
the findings became incontrovertible, 
the trial’s safety committee halted the 
sequential arm. However, this was 
not before 26 people had died in the 
group of 214 – a mortality rate that was 
55% higher than the other two groups 
combined (24 out of 431).
When questioned about the ethics 
of enrolling advanced-stage patients 
into the sequential study arm, Karim 
said any patients could be started on 
ARVs ‘at any time if judged clinically 
necessary’ by the doctors who were 
monitoring them. Generally patients 
who died had low CD4 cell counts – in 
all three study arms.
Mvusi told Izindaba that the 
government’s response has been to 
begin TB treatment and ‘then give 
them up to 2 months before initiating 
ARVs – using the 200 CD4 cell count 
as a benchmark. Those with CD counts 
of less than 100 we’d consider starting 
immediately on ARVs, but we’d first 
initiate TB treatment.’ She said this 
had been policy ‘since the ARV rollout 
began in 2001’. People who were HIV 
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positive but TB negative would be 
offered preventive TB therapy.
WHO and local treatment 
guidelines challenged
The WHO generally recommends 
starting ARVs at a CD4 count of 350, 
giving TB and ARV treatment as soon 
as possible for CD4 counts under 50 
and for CD4 counts of 50 - 200, starting 
ARVs after 2 months of TB treatment. It 
also says that patients with CD4 counts 
over 200 should first complete TB 
treatment. 
The Durban trial has virtually pulled 
the carpet on these guidelines. Said 
Mvusi: ‘What we now need to decide 
is what the ideal CD4 count level is 
to start ARVs in TB patients. It’s still 
out for debate for us. Should we raise 
the bar to 500 and if so, what are the 
implications in terms of costs, numbers, 
staffing, etc.? Or should we look at 
the more conservative WHO level, or 
should we remain where we are?’ She 
added: ‘Some people are saying that if 
you are co-infected and you treat the TB 
(at high CD4 cell count levels), the CD4 
count needs to improve.’
She and her senior staff would be 
meeting with Karim’s research team as 
soon as possible ‘to get clarification on 
the issues I’m raising and to chart the 
way forward’.
Asked about MDR and XDR TB, she 
said this was ‘a different story; we need 
to start them on ARVs at a much higher 
CD4 cell count because of the higher 
mortality’.
Asked how he reached his ’10 000 
lives’ saved per year, Karim said the 
calculation was based on the national 
health department’s figure of 350 000 TB 
cases last year, of which an estimated 
70% were HIV positive.
Of these resulting quarter of a million 
co-infected patients, some 20 - 25% 
would have CD4 cell counts higher than 
500. ‘That leaves you with about 200 000 
people, of whom I estimated that about 
50 000 would reasonably already be on 
ARVs. That leaves you with about  
150 000 who last year were HIV 
positive, had TB and did not get ARVs’. 
If their study finding was implemented, 
these 150 000 people would receive 
ARVs.
The difference in the mortality rate 
between the control arm and the study 
arm of their study was 6.5%, translating 
into the 10 000 lives saved. Karim 
said the study ‘went against all my 
expectations’.
Anomalies resolved with time
‘I thought it would be at the most a 
slight advantage because of immune 
reconstitution syndrome, which can be a 
real problem.’
What the trial does show, is that while 
the mortality rate in the integrated 
treatment arm is actually higher than 
in the sequential arm over the first 3 
months, it reverses over the following 3 
months. The mortality curve lines track 
one another before diverging sharply at 
about 6 months. ‘If you wait until you 
finish the TB treatment, it’s too little, 
too late, so the only way is to start ART 
with TB treatment,’ Karim concluded.
He emphasised that the 55% mortality 
difference was measured on ‘all-cause 
mortality’. If they were able to separate 
out the actual AIDS/TB deaths (a 
virtually impossible task given the 
lack of autopsies and dismal record 
keeping), the difference would have 
almost certainly been bigger.
Mvusi emphasised that the decision 
on when to start ARVs ‘remains with 
the clinician and the individual patient’. 
She wants to thoroughly interrogate 
with Karim’s team the relative merits 
of earlier ART (i.e. helping to deal 
with undiagnosed opportunistic 
infections), and the combined effects 
of opportunistic infections and 
antagonistic drug use. ‘If very low CD4 
cell counts are not properly monitored 
you may kill instead of save people,’ 
she cautioned.
Acting national HIV/AIDS chief, Dr 
Frew Benson (Dr Nomonde Xundu was 
in New York, once again dealing with 
unresolved UNAIDS funding issues), 
told Izindaba he had yet to study the 
Durban trial. However, he was certain it 
‘warrants closer study from our side’.
‘We obviously must look at it 
objectively and develop a policy 
decision based on these findings. We 
welcome any research that can assist 
us to better manage the pandemic,’ he 
added.
The Treatment Action Campaign 
called on the WHO and the South 
African Department of Health to 
integrate the findings into their TB/HIV 
treatment guidelines. It asked that ARVs 
be provided to patients not more than 
2 months after they have started TB 
treatment, if their CD4 count is less than 
500. ‘The Department of Health must 
put measures in place to prepare for the 
increased demand in ARVs that would 
arise from TB patients needing to start 
ARV treatment earlier,’ the TAC added.
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